Concepedia

Janelle Comita-Prevoir

JC

Statistics

Publications

12

Citations

853

H-Index

12

Active since

2008

Affiliations

AstraZeneca (United States)(Current)

Entasis Therapeutics (United States)

AstraZeneca (United Kingdom)

AstraZeneca (Sweden)

University of South Florida

Janelle Comita-Prevoir is an author at AstraZeneca (United States) specializing in antibiotic resistance, medicinal chemistry, and pharmacology.

Publications per year

2008–2021

12

Publications

12

ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii

Thomas F. Durand-Réville, Satenig Guler, Janelle Comita-Prevoir et al. · Nature Microbiology · 2017 · 271 citations

, , +16

Rational design of a new antibiotic class for drug-resistant infections

Thomas F. Durand-Réville, Alita A. Miller, John P. O’Donnell et al. · Nature · 2021 · 140 citations

, , +16

Novel N-Linked Aminopiperidine Inhibitors of Bacterial Topoisomerase Type II: Broad-Spectrum Antibacterial Agents with Reduced hERG Activity

Folkert Reck, Richard A. Alm, Patrick Brassil et al. · Journal of Medicinal Chemistry · 2011 · 103 citations · Full text

, , +17

Novel N-Linked Aminopiperidine Inhibitors of Bacterial Topoisomerase Type II with Reduced p<i>K</i><sub>a</sub>: Antibacterial Agents with an Improved Safety Profile

Folkert Reck, Richard A. Alm, Patrick Brassil et al. · Journal of Medicinal Chemistry · 2012 · 92 citations · Full text

, , +17

Discovery of an Orally Available Diazabicyclooctane Inhibitor (ETX0282) of Class A, C, and D Serine β-Lactamases

Thomas F. Durand-Réville, Janelle Comita-Prevoir, Jing Zhang et al. · Journal of Medicinal Chemistry · 2020 · 61 citations · Full text

, , +17

1–5 of 12